GU Cancers Symposium 2020: Quality of Life in Men Treated for Advanced Prostate Cancer
Posted: Thursday, March 12, 2020
The addition of abiraterone to androgen-deprivation therapy appears to be associated with a better quality of life than adding docetaxel in men with locally advanced or metastatic hormone-sensitive prostate cancer, according to data presented at the 2020 Genitourinary (GU) Cancers Symposium (Abstract 14) in San Francisco. The majority of the impact on quality of life was observed in the first year of treatment. In earlier results of the STAMPEDE trial, there was no evidence that overall survival differed between docetaxel or abiraterone.
“[These results] should be considered when discussing treatment options with patients,” stated Hannah L. Rush, MBChB, of the University College London, and colleagues.
Quality-of-life questionnaires were completed prospectively by 173 men randomly assigned to docetaxel and 342 men assigned to abiraterone from baseline to 2 years. The baseline global quality-of-life scores were similar (77.8 vs. 78.0, respectively); however, the average global quality-of-life score over 2 years was higher in patients receiving abiraterone compared with those receiving docetaxel. Although this difference was statistically significant (+3.9, P = .021), it fell short of the predefined clinically meaningful score difference of at least 4 points.
In cross-sectional analyses at 3 and 6 months, patients receiving abiraterone showed clinically meaningful superior quality of life (+6.6 and +8.0 points) compared with those receiving docetaxel—but not at 1 or 2 years (+1.3 and +4.5 points). The average quality of life for the cohort of patients with metastatic disease (n = 207) was also significantly improved in the abiraterone group (+4.44, P = .036).
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
